Cook Biotech will collaborate with drug-delivery maker AcuityBio on Acuity’s lead lung cancer product, the companies said today.
Acuity’s ABC103 will use Cook Biotech’s proprietary extracellular matrix (ECM) technology. ABC103 is a platform technology designed for localized, sustained drug delivery to prevent post-surgical lung cancer recurrence. It combines approved/ cleared surgical staple-line buttress, drug-eluting polymers and a chemotherapeutic drug, paclitaxel.
The FDA has granted ABC103 orphan drug designation for this indication. Phase I clinical testing of is scheduled to begin in late 2019. Acuity is developing other applications for the ABC drug-delivery platform.